Theoretical stack · Weight Loss & Body Composition

GLP-1 + Amylin Combination Therapy

Tirzepatide + Pramlintide + Cagrilintide

Moderate–Strong · By · Last reviewed: May 2026

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

The pharmacologic logic behind CagriSema and the broader incretin-plus-amylin direction in modern obesity medicine: pair the GLP-1 (or GLP-1/GIP) appetite-suppression mechanism with amylin's complementary satiety and gastric-emptying biology.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Tirzepatide
Dual GIP/GLP-1 receptor agonist; ~21% weight loss in SURMOUNT-1, currently the deepest FDA-approved obesity agent
FDA-approved · Mounjaro / Zepbound
Pramlintide
FDA-approved synthetic amylin analog (Symlin); the longest-validated amylin-pathway therapy
FDA-approved · TID injection
Cagrilintide
Long-acting amylin analog being developed by Novo Nordisk as a once-weekly amylin agonist for obesity
Phase 3 · Investigational

Mechanistic rationale

Native amylin is co-secreted with insulin from pancreatic beta cells and contributes to postprandial satiety, slowed gastric emptying, and glucagon suppression, biology that overlaps with but is mechanistically distinct from GLP-1. The GLP-1-plus-amylin pairing has been the most-discussed pharmacological combination strategy in obesity medicine since the development of cagrilintide gave Novo Nordisk a long-acting amylin agonist suitable for combination dosing.

CagriSema (cagrilintide + semaglutide as a fixed combination) is the most-watched embodiment of this logic, with Phase 3 readouts in obesity and T2D ongoing. Tirzepatide adds the GIP arm to the GLP-1 arm in a single molecule; pairing tirzepatide with an amylin agonist takes the combination logic one step further. Pramlintide is the practical, currently-available amylin analog for users with access to off-label combination.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers, controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

Potential benefits and risks

Potential benefits

  • Complementary mechanisms — GLP-1 and amylin act on different appetite circuits
  • Strong individual-compound evidence, particularly tirzepatide
  • CagriSema Phase 2 data supports the additive concept
  • Practical option for plateau-busting after GLP-1 monotherapy effects level off

Potential risks

  • Combination-specific safety data for tirzepatide + amylin is not yet established
  • Pramlintide requires three-times-daily injection, substantial regimen burden
  • GI tolerability stacks: both classes produce nausea, and combining intensifies it
  • Hypoglycemia risk in patients on insulin or sulfonylureas, particularly with pramlintide
  • Cost and access issues compound when combining two specialty agents

Open questions

  • How does tirzepatide + cagrilintide compare to tirzepatide + pramlintide in head-to-head outcomes?
  • Is the additive weight-loss effect proportional or saturating at higher doses?
  • What are the long-term cardiovascular and renal outcomes of incretin-plus-amylin combinations?
  • Will CagriSema Phase 3 confirm the Phase 2 additive signal at scale?

The takeaway

The GLP-1 + amylin direction is the most evidence-grounded combination strategy in modern obesity pharmacology, complementary mechanisms, strong per-compound evidence, supportive Phase 2 combination data (CagriSema), and the practical availability of pramlintide for users wanting to explore the logic now. Practically speaking, this is one of the more defensible combination concepts on the site, but combination-specific Phase 3 data is still being generated, and the regimen burden (especially with pramlintide's TID injection) is non-trivial.

References

  1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2021;398(10317):2160-2172. https://pubmed.ncbi.nlm.nih.gov/34798033/
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Aronne LJ, et al. Pramlintide as an adjunct to lifestyle intervention in the management of obesity. J Clin Endocrinol Metab. 2007;92(8):2977-2983. https://pubmed.ncbi.nlm.nih.gov/17504894/
  4. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in T2D. Lancet. 2023;402(10403):720-730. https://pubmed.ncbi.nlm.nih.gov/?term=cagrisema